Showing 7301-7310 of 8834 results for "".
- Upsher-Smith Introduces Isotretinoin Capsules in UShttps://practicaldermatology.com/news/upsher-smith-introduces-isotretinoin-capsules-in-us/2460960/Isotretinoin capsules AB2-rated to the branded product Absorica® (isotretinoin) are now available in 10mg, 20mg, 30mg, and 40mg strengths from
- Allergan Aesthetics Supports Breast Cancer Awareness with New Campaign, Initiativeshttps://practicaldermatology.com/news/allergan-aesthetics-supports-breast-cancer-awareness-with-new-campaign-initiatives/2460954/Allergan Aesthetics’ Power of You campaign is kicking off a new series of initiatives and partnerships to support breast cancer awareness. The Power of You campaign showcases real women and their authentic stories of courage, strength, and community as they embark on their journey
- ASDSA Lauds FDA for Safety Communication on Needle-less Deviceshttps://practicaldermatology.com/news/asdsa-lauds-fda-for-safety-communication-on-needle-less-devices/2460952/The American Society for Dermatologic Surgery Association (ASDSA) applauds the U.S. Food and Drug Administration (FDA) for sending out a safety communication regarding needle-less devices, such as hyaluron pens (HA pens) for injection of dermal fillers. ASDSA had earlier
- Aveeno Launches #SkinVisibility Campaignhttps://practicaldermatology.com/news/aveeno-launches-skinvisibility-campaign/2460948/Aveeno’s new #SkinVisibility campaign aims to address the underdiagnosis, care and treatment of eczema on Black skin. The campaign, which launches during Eczema Awareness Month, underscores the brand's pledge to help 100,000 people with eczema find relief&n
- Investigational Agents Show Benefit in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/investigational-agents-show-benefit-in-chronic-spontaneous-urticaria/2460938/Complete control of chronic spontaneous urticaria (CSU) is associated with improvements in key HRQoL measures, such as overall quality of life, sleep interference, activity interference and work impairment, while a marked decline in these improvements to quality of life is seen among patients wit
- No Concerning Safety Signals for Timber's Topical Isotretinoin in Congenital Ichthyosishttps://practicaldermatology.com/news/no-concerning-safety-signals-for-timbers-topical-isotretinoin-in-congenital-ichthyosis/2460934/Phase 2a study results demonstrate no concerning safety signals and no evidence of significant systemic exposure to isotretinoin or tretinoin after 12 weeks of treatment with Timber Pharmaceuticals’ topical isotretinoin formulation (TMB-001) in pa
- Data Show Continuous Response to LEO's Tralokinumab in Adults with ADhttps://practicaldermatology.com/news/data-show-continuous-response-to-leos-tralokinumab-in-adults-with-ad/2460933/After two years of continuous treatment with tralokinumab, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity, and sleep interference, according to interim findings from the Phase 3 ECZTEND trial presented as an oral presenta
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the
- Garnier Launches New Green Beauty Campaignhttps://practicaldermatology.com/news/garnier-launches-new-green-beauty-campaign/2460931/Garnier is launching a new educational campaign on how to live a greener life with content produced by National Geographic CreativeWorks. The series, which will premiere at Expo 2020 Dubai and roll out worldwide, aims to share expert knowledge and real-world advice on key sustainability
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disord